Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events
Open Access
- 12 September 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 67 (2) , 612-622
Abstract
The clinical benefit of sorafenib in patients with hepatocellular carcinoma (HCC) has been undervalued due to the absence of complete responses, even though patients who develop early dermatologic reactions have shown to have a positive outcome. In addition, sorafenib is described as an antiangiogenic drug, but it also acts on immunological cells. Thus, the goal of this study was to assess the complete response rate in a retrospective cohort of HCC patients treated with sorafenib and to describe the profile of the patients who achieve complete response for identifying factors related to this event and their connection with the immunological profile of sorafenib. Ten Spanish centers submitted cases of complete response under sorafenib. The baseline characteristics, development of early dermatologic reactions, and cause of treatment discontinuation were annotated. Radiological images taken before starting sorafenib, at first control, after starting sorafenib, at the time of complete response, and at least 1 month after treatment were centrally reviewed. Of the 1119 patients studied, 20 had been classified as complete responders by the centers, but eight of these patients were excluded after central review. Ten patients had complete disappearance of all tumor sites, and two had just a small residual fibrotic scar. Thus, 12 patients were classified as complete responders (58% HCV, median age 59.7 years, 83.4% Child‐Pugh class A, Eastern Cooperative Oncology Group performance status 0 91.7%, and Barcelona Clinic Liver Cancer stage C 83.3%). The median overall survival and treatment duration were 85.8 and 40.1 months, respectively. All but one patient developed early dermatologic reactions, and seven patients discontinued sorafenib after achieving complete response due to adverse events, patient decision, or liver decompensation. Conclusion: Complete response affects 1% of patients with HCC who are treated with sorafenib. The association of complete response with early dermatologic reactions supports the role of a specific immune/inflammatory patient profile in the improved response to sorafenib. (Hepatology 2018;67:612‐622).Keywords
Funding Information
- Instituto de Salud Carlos III (PI15/00145, PI14/00962)
- AECC (PI044031)
This publication has 32 references indexed in Scilit:
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in ItalyHepatology, 2010
- A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma†Hepatology, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Interdependence of hypoxic and innate immune responsesNature Reviews Immunology, 2009
- Regulation and Function of NF-κB Transcription Factors in the Immune SystemAnnual Review of Immunology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- NF-κB and cancer — identifying targets and mechanismsCurrent Opinion in Genetics & Development, 2008
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000